Theriva Biologics, Inc. (NYSE: TOVX)

Theriva Biologics, Inc. (TOVX) is a clinical-stage biopharmaceutical company operating in the healthcare industry, specifically focused on developing therapeutics to treat cancer and related diseases in areas of high unmet need. The company's main business activities revolve around its oncology platform, which is based on oncolytic virotherapy - a novel class of anticancer agents that exploit the ability of certain viruses to kill tumor cells and trigger an anti-tumor immune response.

Theriva Biologics' primary products are derived from its oncolytic adenovirus platform, most notably VCN-01. VCN-01 is a clinical-stage oncolytic human adenovirus that has been modified to express an enzyme, PH20 hyaluronidase, which degrades hyaluronic acid in the tumor stroma. This allows the virus to penetrate and spread throughout the tumor, making it more effective at targeting and destroying cancer cells. VCN-01 has been administered to 116 patients across multiple Phase 1 clinical trials and a Phase 2 VIRAGE trial, including patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma.

The company's oncology pipeline is primarily focused on the treatment of solid tumors, such as pancreatic ductal adenocarcinoma (PDAC), head and neck squamous cell carcinoma (HNSCC), and retinoblastoma. In PDAC, VCN-01 has shown promising results in Phase 1 clinical trials, with an overall response rate (ORR) of 50% and a median progression-free survival (PFS) of 6.7 months. Theriva Biologics is currently conducting a Phase 2b randomized, open-label, controlled clinical trial, VIRAGE, evaluating VCN-01 in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel) as a first-line therapy for patients with metastatic PDAC.

In HNSCC, VCN-01 is being evaluated in combination with durvalumab, a human monoclonal antibody that inhibits binding of PD-L1, in a Phase 1 clinical trial. This study aims to evaluate the safety, tolerability, and recommended Phase 2 dose of VCN-01 combined with durvalumab in patients with recurrent/metastatic HNSCC.

In retinoblastoma, VCN-01 is being evaluated in a Phase 1 clinical trial as an intravitreal injection in patients with intraocular retinoblastoma refractory to systemic, intra-arterial or intravitreal chemotherapy, or radiotherapy. This trial has shown promising results, with one patient treated with VCN-01 experiencing a complete regression lasting more than 30 months.

Theriva Biologics' competitive advantages include its oncolytic adenovirus platform, which has shown promising results in clinical trials, as well as its ability to deliver a payload of hyaluronidase, which degrades hyaluronic acid in the tumor stroma, allowing the virus to penetrate and spread throughout the tumor. Additionally, the company's products have been granted Orphan Drug designation by the FDA for the treatment of pancreatic cancer and retinoblastoma.

The company's customers include patients with various types of cancer, as well as healthcare providers and researchers involved in the development and treatment of cancer. Theriva Biologics' products are being developed in collaboration with several institutions, including the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL), and Washington University School of Medicine in St. Louis.

Theriva Biologics has a growing patent estate, with over 130 U.S. and foreign patents and over 65 U.S. and foreign patents pending. The company's intellectual property is focused on its oncolytic adenovirus platform, as well as its proprietary oral capsule prophylactic therapy, SYN-004.